Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

61.05
+1.312.19%
Volume:421.22K
Turnover:25.51M
Market Cap:10.15B
PE:-17.54
High:61.25
Open:60.60
Low:59.70
Close:59.74
52wk High:86.74
52wk Low:41.71
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.89
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:23.07
PE(LYR):-25.64

Loading ...

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Viking Therapeutics (VKTX)

TIPRANKS
·
Apr 30

Analyst Reiterates Buy Rating on Ionis Pharmaceuticals, Maintains $105 Price Target on Strong Q1 and Upgraded Olezarsen Outlook

TIPRANKS
·
Apr 30

Ionis Pharmaceuticals reports Q1 EPS (56c), consensus (77c)

TIPRANKS
·
Apr 29

Ionis Pharmaceuticals raises FY26 revenue view $875M-$900M from $800M-$825M

TIPRANKS
·
Apr 29

Ionis Q1 revenue rises 87% on R&D payments boost

Reuters
·
Apr 29

Ionis Q1 FY26 net loss narrows 37% to $93 million; revenue rises 87% to $246 million

Reuters
·
Apr 29

GUIDANCE: (IONS) Ionis Pharmaceuticals Expects 2026 Total Revenue Range $875M - $900M, vs. FactSet Est of $808.5M

MT Newswires Live
·
Apr 29

Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q1 Loss $0.56 a Share, vs. FactSet Est of $0.88 Loss

MT Newswires Live
·
Apr 29

Ionis Pharmaceuticals Q1 Adj. EPS $(0.30) Beats $(0.91) Estimate, Sales $246.000M Beat $195.628M Estimate

Benzinga Earnings
·
Apr 29

Ionis Reports First Quarter 2026 Financial Results and Highlights Progress on Key Programs

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Inc - Lowers 2026 Non-Gaap Operating Loss Guidance to $425-$475 Mln From $500-$550 Mln

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Q1 Revenue USD 43 Million VS. Ibes Estimate USD 195.6 Million

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Q1 Operating Income USD -118 Million

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Outlook FY Revenue USD 875-900 Million

THOMSON REUTERS
·
Apr 29

Ionis Pharmaceuticals Inc - Raises 2026 Total Revenue Guidance to $875-$900 Mln From $800-$825 Mln

THOMSON REUTERS
·
Apr 29

Corrected-Ionis Pharmaceuticals Q1 Revenue USD 246 Million VS. Ibes Estimate USD 195.6 Million (Corrects Amount)

THOMSON REUTERS
·
Apr 29

Ionis partner GSK announces bepirovirsen NDA accepted for priority review

TIPRANKS
·
Apr 28

Ionis partner GSK’s bepirovirsen wins FDA Priority Review for hepatitis B NDA

Reuters
·
Apr 28

Ionis Pharmaceuticals Inc: Pdufa Date of October 26, 2026

THOMSON REUTERS
·
Apr 28

Ionis Partner GSK Announces Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by U.S. FDA as a Potential First-in-Class Medicine for Chronic Hepatitis B

THOMSON REUTERS
·
Apr 28